Is the problem a lack of transparency, or a lack of timely information? They aren’t able to reveal it before the decision is made, and there is a very high cost to rapid turnaround.
I had practically finished this post before Claire Zabel’s comment. And since the purchase was was made a while back I was of the opinion EVF should’ve already written something about it. But since it’s through Open Phil and only finalized this year plus with delay in grant publishing, that changes things. It still comes across as a ‘failure’ (I don’t want to sound this harsh) that there is so much delay, but perhaps there are good reasons for it. Still, I hope this post has some usefulness so I decided to publish it anyway, as I would still like to see more transparency and clearer reasoning. But the case is potentially less strong as I preciously thought. I’ll add this info to the post.
Is the problem a lack of transparency, or a lack of timely information? They aren’t able to reveal it before the decision is made, and there is a very high cost to rapid turnaround.
I had practically finished this post before Claire Zabel’s comment. And since the purchase was was made a while back I was of the opinion EVF should’ve already written something about it. But since it’s through Open Phil and only finalized this year plus with delay in grant publishing, that changes things. It still comes across as a ‘failure’ (I don’t want to sound this harsh) that there is so much delay, but perhaps there are good reasons for it. Still, I hope this post has some usefulness so I decided to publish it anyway, as I would still like to see more transparency and clearer reasoning. But the case is potentially less strong as I preciously thought. I’ll add this info to the post.